Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Anti-stroke drug effective treatment for middle-ear infections, researchers say

  • Implantable micro-device to monitor oxygen in glioma to improve treatment outcomes

  • Study on neurogenesis in the olfactory bulb

  • Raising a glass to the holidays: Research finds extra alcohol sold, consumed on holidays

  • Human stem cell model reveals molecular cues critical to neurovascular unit formation

  • Scientists create mice with a major genetic cause of ALS, frontotemporal dementia

  • Blood test for Alzheimer's one step closer

  • Switching off brain circuit renders mice 'out of touch' with environment

  • Facebook status updates reveal low self-esteem and narcissism

  • Anticipating temptation may reduce unethical behavior, research finds

  •